Author

Lucrecia Nardone

OpenAlex ID: A5124763641

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

2021 · Stefano Del Prato, Steven E Kahn, et al. · The Lancet · 748

Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial

2026 · Rodica Pop-Busui, Søren Rasmussen, et al. · JAMA Internal Medicine · 18

Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial

2026 · Sharon L. Mulvagh, Silvio E. Inzucchi, et al. · JAMA Cardiology · 6

[CAPTURE Study: Argentine results on prevalence of cardiovascular disease in type 2 diabetes mellitus].

2022 · Guillermo Dieuzeide, Jorge Waitman, et al. · PubMed · 1

First and Subsequent Major Cardiovascular Events With Oral Semaglutide in High-Risk Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial

2026 · Nikolaus Marx, John E. Deanfield, et al. · JAMA Cardiology

O14 Función renal en personas con diabetes tipo 2 con y sin enfermedad cardiovascular: un análisis post hoc de la población argentina del estudio CAPTURE

2020 · Guillermo Dieuzeide, Luis De Loredo, et al. · Revista de la Sociedad Argentina de Diabetes

Works count: 6

Citation count: 773

H-index: 3

I10-index: 2